Deciphering Drug Targets For Alzheimers Disease

This book offers a comprehensive exploration of malaria, a life-threatening disease affecting millions globally, with a focus on the parasitic organisms of the genus Plasmodium that cause it. It discusses the challenges posed by the disease, especially in economically developing regions, and delves into the biology and pathophysiology of the Plasmodium species, including their genetic flexibility and resistance to treatments. Special attention is given to P. falciparum, the most dangerous of these parasites, detailing its complex life cycle, interaction with human hosts, and the severe clinical manifestations it can induce. The book further explores the global health concern of antimalarial drug resistance, highlighting the WHO's efforts in combating the disease and the necessity for novel treatments. Innovative research directions, such as targeting the unique organelles of Plasmodium like the apicoplast and employing proteasome inhibitors, are thoroughly examined as potential strategies in the development of new antimalarial drugs. Additionally, it addresses the critical role of the hemoglobin digestion process in the parasite's lifecycle, presenting it as a promising target for therapeutic intervention. This work is an essential resource for researchers, clinicians, and policymakers involved in malaria control and drug development, providing insights into the current challenges and future directions in the fight against this endemic disease.

This book offers a comprehensive exploration of malaria, a life-threatening disease affecting millions globally, with a focus on the parasitic organisms of the genus Plasmodium that cause it. It discusses the challenges posed by the disease, especially in economically developing regions, and delves into the biology and pathophysiology of the Plasmodium species, including their genetic flexibility and resistance to treatments. Special attention is given to P. falciparum, the most dangerous of these parasites, detailing its complex life cycle, interaction with human hosts, and the severe clinical manifestations it can induce. The book further explores the global health concern of antimalarial drug resistance, highlighting the WHO's efforts in combating the disease and the necessity for novel treatments. Innovative research directions, such as targeting the unique organelles of Plasmodium like the apicoplast and employing proteasome inhibitors, are thoroughly examined as potential strategies in the development of new antimalarial drugs. Additionally, it addresses the critical role of the hemoglobin digestion process in the parasite's lifecycle, presenting it as a promising target for therapeutic intervention. This work is an essential resource for researchers, clinicians, and policymakers involved in malaria control and drug development, providing insights into the current challenges and future directions in the fight against this endemic disease.

The COVID-19 pandemic caused by the SARS-CoV-2 virus has affected nearly every country and territory in the world. Although worldwide vaccination efforts have reduced the risk of serious disease outcomes, disparities in distribution have led to multiple waves of SARS-CoV-2 outbreaks and the emergence of variants of concern, some of which have enhanced infectivity and ability to evade existing vaccines. Hence there is an increasing interest in understanding the evolution of viruses like SARS-CoV-2, as well as improving our capacity to effectively current and manage future pandemics.

This book is an invaluable clinical reference for the therapeutic management of gastrointestinal and liver diseases which the gastroenterologist and trainee encounter in their practice. Various drugs and their interactions with their intended site and also with other drugs are discussed from a practical point of view.

New and emerging directions in pharmaceutical research to better treat schizophrenia
Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics.